A Variation in the ABCC8 Gene Is Associated with Type 2 Diabetes Mellitus and Repaglinide Efficacy in Chinese Type 2 Diabetes Mellitus Patients

Xueyan Zhou¹, Chunxia Chen¹, Di Yin¹, Feng Zhao¹, Zejun Bao¹, Yun Zhao¹, Xi Wang¹, Wei Li², Tao Wang¹, Yingliang Jin¹, Dongmei Lv³, Qian Lu¹ and Xiaoxing Yin¹

Abstract: Previous studies have suggested that variations in the ABCC8 gene may be closely associated with T2DM susceptibility and repaglinide response. However, these results have not been entirely consistent, and there are no related studies in a Chinese population, suggesting the need for further exploration. The current study investigated the associations of the ABCC8 rs1801261 polymorphism with type 2 diabetes mellitus (T2DM) susceptibility and repaglinide therapeutic efficacy in Chinese Han T2DM patients.

Methods A total of 234 T2DM patients and 105 healthy subjects were genotyped for ABCC8 rs1801261 polymorphism by a polymerase chain reaction-restriction fragment length polymorphism assay. A total of 70 patients with the same genotypes of CYP2C8*3 139Arg and OATP1B1 521TT were randomized to orally take 3 mg repaglinide per day (1 mg each time before meals) for 8 consecutive weeks. The pharmacodynamic parameters of repaglinide and biochemical indicators were then determined before and after repaglinide treatment.

Results The frequency of ABCC8 rs1801261 allele was higher in T2DM patients than in the control subjects (22.6% vs.11.0%, p<0.01). After repaglinide treatment, T2DM patients carrying genotype CT showed a significantly attenuated efficacy on FPG (p<0.01) and HbA1c (p<0.01) compared with those with genotype CC.

Conclusion These results suggested that the ABCC8 rs1801261 polymorphism might influence T2DM susceptibility and the therapeutic effect of repaglinide in Chinese Han T2DM patients. This study was registered in the Chinese Clinical Trial Register on May 14, 2013 (No. ChiCTR-CCC13003536).

Key words: ABCC8, gene polymorphism, type 2 diabetes mellitus, repaglinide, sulfonylurea receptor 1, insulin secretion

Introduction

Type 2 diabetes mellitus (T2DM) and its associated complications pose a major global healthcare burden. It is estimated that 592 million people worldwide will be affected by diabetes by the year 2035, and a majority of the affected will be Asians (1, 2). T2DM is generally recognized as a multifactorial, polygenic disease (3). Genetic factors play an important role in the development of T2DM (4). Polymorphisms in genes encoding proteins involved in the pancreatic β-cell function, insulin function and glucose metabolism might influence the susceptibility of T2DM (5, 6).

Among these genes, the ATP-binding cassette superfamily transporter family C8 (ABCC8) has come under attention (7). It has been reported that sulfonylurea receptor 1
in the pancreatic β-cell function. Because the adenosine triphosphatase (ATP)-sensitive potassium (K₁) channels (K_{ATP}) on the islet β-cell membrane are composed of ion channels formed by SUR1 and Kir6.2, SUR1 plays an important role in modulating ATP-sensitive potassium channels and insulin release (8). Pathogenic mutations in the SUR1 gene can cause various types of diabetes, such as hyperinsulinemic hypoglycemia of infancy and T2DM (9). Thus, abnormal SUR1 (ABCC8) can lead to disturbance of potassium channel and insulin secretion (10). It has been reported that ABCC8 rs1801261 polymorphisms are correlated with the risk of T2DM in Danish and Canadian populations (11, 12). However, four previous studies involving Dutch Caucasian, English, North Indian and Finnish populations have shown that the ABCC8 rs1801261 site is not associated with the risk of T2DM (13-16). These results are not entirely consistent, and there are no related studies in Chinese populations, underscoring the need for further exploration.

Furthermore, most T2DM patients often eventually require hypoglycemic agents in order to maintain an acceptable glycemic level and to reduce the risk of development and progression of disease complications (17). However, an identical antidiabetic therapy regimen might bring in various therapeutic responses and sometimes even serious adverse reactions, which is partly a result of genetic factors (18). Repaglinide is an insulin secretagogue that is widely used in the treatment of T2DM in clinical practice. It can enhance insulin secretion from pancreatic β-cells by combining with SUR1, thereby inhibiting K_{ATP} channels and activating calcium (Ca⁺) channels (19, 20). It is often combined with metformin to treat T2DM patients who fail sulfonylurea treatment by reducing postprandial hyperglycemia (21).

Recently, more attention has been gradually given to the presence of considerable interindividual variability in repaglinide therapeutic efficacy (22). Some researchers have attributed this to the genetic polymorphisms of cytochrome P450 2C8 (CYP2C8) and organic anion-transporting polypeptide 1B1 (OATP1B1) because of their influence on the pharmacokinetic process of repaglinide (23, 24). In addition, it has been found that KCNJ11, KCNQ1, NOS1AP, NAMPT, NeuroD1 and other genetic polymorphisms can affect the efficacy of repaglinide (25-29). However, these studies have been unable to fully elucidate the mechanism of action by which the same repaglinide therapy results in various therapeutic responses. By targeting islet β-cells, repaglinide might produce various therapeutic effects, depending on the genetic polymorphism of ABCC8.

In summary, repaglinide can bind to SUR1 to stimulate insulin release in pancreatic β-cells. ABCC8 gene coding SUR1 may therefore play a critical role in glucose metabolism, and ABCC8 gene polymorphisms may be related to T2DM susceptibility and individual differences in the effects of repaglinide. The present study investigated the association between ABCC8 rs1801261 polymorphisms and T2DM in Chinese T2DM patients and explored the effects of these polymorphisms on repaglinide efficacy in order to provide a genetic pharmacology basis for gene-directed individualized medication.

Materials and Methods

Subjects

A total of 234 unrelated T2DM patients (mean age: 49.94 ±0.79 years; 140 men and 94 women) and 105 healthy controls (mean age: 46.60±1.19 years; 62 men and 43 women) were enrolled in this study. The case group and healthy control group were collected from the Department of Endocrinology and Physical Examination of the Affiliated Hospital of Xuzhou Medical College. For the allocation of the participants, a computer-generated list of random numbers was prepared by an investigator with no clinical involvement in the trial. The study was registered in the Chinese Clinical Trial Register (No. ChiCTR-CCC13003536) and performed in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of the Affiliated Hospital of Xuzhou Medical College. Written informed consent was obtained from each subject before the study.

T2DM was diagnosed according to the 1999 World Health Organization Criteria for hyperglycemia, as follows: fasting plasma glucose (FPG) ≥7.0 mmol/L and/or 2-hour plasma glucose post-oral glucose tolerance test (2-h PG) ≥11.1 mmol/L. Patients who participated in this study had a body mass index (BMI) of 18.5-30 kg/m² and had not received an insulin secretagogue and/or agonists or inhibitors of CYP2C8, CYP3A4 and OATP1B1 in the past 3 months. The exclusion criteria were receiving insulin treatment, pregnancy or lactation, and a history of ketoacidosis, acute myocardial infarction, congestive heart failure, trauma or liver/kidney diseases. The inclusion criteria for healthy control subjects were (i) a BMI of 18.5-30 kg/m² and (ii) normal glucose levels (FPG <6.1 mmol/L and 2-h PG level <7.8 mmol/L). Control subjects with high blood pressure and hyperlipidemia were excluded from this study.

Clinical laboratory tests

T2DM patients received repaglinide (trade name: Novo; Novo Nordisk, Copenhagen, Denmark) 1 mg at 15 minutes before meals orally 3 times a day for 8 weeks. During treatment, their diet and exercise habits remain unchanged. Antihypertensive drugs or hypolipidemic drug users continued to take their current medications with the dose unchanged. Venous blood samples were collected after fasting overnight and again 2 hours after a standard breakfast (100 g sugar-free steamed bread). Parameters were measured before and eight weeks after repaglinide administration.

Clinical observation index and determination method

Plasma glucose and lipid profiles, including triglyceride (TG), total cholesterol (TC), low-density lipoprotein chole-
primer for mutant variants: 5′-AAGCATATTACCCATGAA-3′.

**Statistical analyses**

The allele frequencies were determined by gene calculating, and Hardy-Weinberg equilibrium tests were performed. Statistical analyses were performed using the SPSS software program (version 21.0 for Windows; IBM, NY, USA). The baseline characteristics in T2DM patients and healthy subjects were performed using a two-sample t-test (27). The paired Student’s t-test and a one-way analysis of variance (ANOVA) were performed to assess the effects of repaglinide on the metabolic parameters of subjects with various genotypes. Variables with a normal distribution were analyzed by the two-sample t-test or one-way ANOVA, while those with a skewed distribution were analyzed by the Mann-Whitney U test or Kruskal-Wallis test (30). All continuous variables were summarized as the mean and standard deviation. Statistical power was calculated using the PASS software program (http://www.ncss.com). A value of p <0.05 was considered statistically significant.

**Results**

### Clinical characteristics

The clinical and biochemical characteristics of all participants are listed in Table 1. The values of BMI, WHR, FPG, TC, TG and LDL-c were higher in patients with T2DM than in healthy subjects (all p<0.01). However, no significant differences were found between the two groups in the age, sex distribution or plasma HDL-c concentration.

### Allelic frequency analyses

In the present study, 234 T2DM patients (140 men and 94 women) and 105 healthy subjects (62 men and 43 women) were genotyped for the ABCC8 rs1801261 polymorphism. The genotype distribution in each group was consistent with the Hardy-Weinberg equilibrium, and the samples were representative (p>0.05). The C allele frequency of ABCC8 rs1801261 was 77.4% in T2DM patients and 89.0% in healthy subjects.

### Assessment of baseline parameters in T2DM patients with different ABCC8 rs1801261 genotypes

In the present study, the baseline clinical characteristics of the 234 T2DM patients with different ABCC8 rs1801261 genotypes were analyzed by a one-way ANOVA or the Kruskal-Wallis test. There was no association between ABCC8 rs1801261 polymorphisms and the sex, age, WHR, BMI, FPG, PPG, fasting serum insulin (FINS), postprandial serum insulin (PINS), HOMA-IR, HbA1c, TG, TC or

### Table 1. Clinical Characteristics of Type 2 Diabetes Mellitus Patients and Healthy Subjects.

| Parameter | Healthy controls | T2DM patients | p value |
|-----------|------------------|---------------|---------|
| N (male/female) | 105 (62/43) | 234 (140/94) | 0.892a |
| Age (years) | 47.13±1.078 | 49.81±0.789 | 0.053 |
| BMI (kg/m²) | 23.52±0.32 | 25.98±0.26 | 0.000** |
| WHR | 0.82±0.008 | 0.92±0.004 | 0.000** |
| FPG (mmol/L) | 5.22±0.05 | 9.58±0.17 | 0.000** |
| TC (mmol/L) | 4.77±0.91 | 5.29±0.09 | 0.006** |
| TG (mmol/L) | 1.27±0.09 | 2.46±0.18 | 0.000** |
| HDL-c (mmol/L) | 1.33±0.03 | 1.41±0.03 | 0.367* |
| LDL-c (mmol/L) | 2.69±0.05 | 3.16±0.07 | 0.000** |

Data are given as mean±standard error. p values are determined by Student’s t-test. *p<0.05, **p<0.01. p values are determined by Mann-Whitney U test.

p values are determined by Pearson chi-square test. BMI: body mass index, WHR: waist to hip ratio, FPG: fasting plasma glucose, TG: triglyceride, TC: total cholesterol, HDL-c: high-density lipoprotein-cholesterol, LDL-c: low-density lipoprotein-cholesterol.
**Table 2.** Comparison of Genotype and Frequencies of \(ABCC8\) rs1801261 Polymorphism between Type 2 Diabetes Mellitus Patients and Healthy Subjects.

| Genotypes     | Healthy controls (n=105) (%) | T2DM patients (n=234) (%) | \(p\) value |
|---------------|------------------------------|---------------------------|-------------|
| **ABCC8 rs1801261** |                              |                           |             |
| CC            | 82 (78.10)                   | 128 (54.70)               |             |
| CT            | 23 (21.90)                   | 106 (45.30)               | 0.000***     |
| **Alleles**   |                              |                           |             |
| C             | 187 (89.00)                  | 362 (77.40)               |             |
| T             | 23 (11.00)                   | 106 (22.60)               |             |

The allelic frequencies are indicated in absolute values (percentage). *p values were determined by Pearson chi-square test. **p < 0.01.

**Table 3.** The Baseline of Characteristics in T2DM Patients with Various \(ABCC8\) rs1801261 Genotypes.

| Parameter | ABC8 rs1801261 genotypes | \(p\) value |
|-----------|--------------------------|-------------|
| N (male/female) | 128 (75/53) | 106 (65/41) | 0.672b |
| Age (years) | 50.12±1.04 | 49.44±1.20 | 0.672 |
| BMI (kg/m²) | 26.10±0.34 | 25.73±0.38 | 0.502a |
| WHR | 0.92±0.05 | 0.91±0.05 | 0.829a |
| FPG (mmol/L) | 9.72±0.24 | 9.33±0.23 | 0.350a |
| PPG (mmol/L) | 15.61±0.38 | 15.84±0.39 | 0.499a |
| HbA1c (%) | 9.46±0.19 | 9.33±0.18 | 0.592a |
| HOMA-IR | 8.88±1.03 | 8.49±1.09 | 0.256a |
| TC (mmol/L) | 5.27±0.11 | 5.26±0.14 | 0.712a |
| TG (mmol/L) | 2.48±0.28 | 2.40±0.18 | 0.899a |
| HDL-c (mmol/L) | 1.44±0.03 | 1.35±0.04 | 0.030**a |
| LDL-c (mmol/L) | 3.22±0.09 | 3.05±0.10 | 0.291a |

| Parameter | ABC8 rs1801261 genotypes | \(p\) value |
|-----------|--------------------------|-------------|
| N (male/female) | 128 (75/53) | 106 (65/41) | 0.672b |
| Age (years) | 50.12±1.04 | 49.44±1.20 | 0.672 |
| BMI (kg/m²) | 26.10±0.34 | 25.73±0.38 | 0.502a |
| WHR | 0.92±0.05 | 0.91±0.05 | 0.829a |
| FPG (mmol/L) | 9.72±0.24 | 9.33±0.23 | 0.350a |
| PPG (mmol/L) | 15.61±0.38 | 15.84±0.39 | 0.499a |
| HbA1c (%) | 9.46±0.19 | 9.33±0.18 | 0.592a |
| HOMA-IR | 8.88±1.03 | 8.49±1.09 | 0.256a |
| TC (mmol/L) | 5.27±0.11 | 5.26±0.14 | 0.712a |
| TG (mmol/L) | 2.48±0.28 | 2.40±0.18 | 0.899a |
| HDL-c (mmol/L) | 1.44±0.03 | 1.35±0.04 | 0.030**a |
| LDL-c (mmol/L) | 3.22±0.09 | 3.05±0.10 | 0.291a |

- Data are given as mean±standard error. \(p\) values are determined by Student’s t-test. \*p values are determined by Mann-Whitney U test. \**p values are determined by Pearson chi-square test. \*p<0.05, \**p<0.01.
- FPG: fasting plasma glucose, PPG: postprandial plasma glucose, FINS: fasting serum insulin, PINS: postprandial serum insulin, HOMA-IR: homeostasis model assessment for insulin resistance, HbA1c: glycated hemoglobin, TG: triglyceride, TC: total cholesterol, HDL-c: high-density lipoprotein-cholesterol, LDL-c: low-density lipoprotein-cholesterol

**Effects of \(ABCC8\) rs1801261 polymorphisms on the efficacy of repaglinide in T2DM patients**

To exclude the potential influence of OATP1B1 and CYP2C8*3 genetic polymorphisms, 70 T2DM patients with different \(ABCC8\) rs1801261 genotypes but the same OATP1B1 521TT and CYP2C8*3 139Arg genotypes (60 CT carriers and 10 CC carriers) were randomly selected to participate in the present study. After 8 weeks of repaglinide therapy, these patients showed markedly declined values for FPG (p<0.01), PPG (p<0.01), HbA1c (p<0.01), TC (p<0.01), TG (p<0.05) and HOMA-IR (p<0.01) compared with before treatment (Table 4). The effects of repaglinide on FPG were weaker in \(ABCC8\) rs1801261 CT heterozygotes than in CC genotype carriers (p<0.01, Table 5, Figure a), and patients with CC genotypes had significantly lower HbA1c levels than those with the CT genotype (p<0.05, Table 5, Figure b).

**Discussion**

Polymorphisms of genes related to insulin secretion and resistance might influence the susceptibility of T2DM and the therapeutic efficacy of repaglinide. This present study with newly identified Chinese type 2 diabetes patients showed that the variant of rs1801261 in \(ABCC8\) was associated with the susceptibility of T2DM and the efficacy of repaglinide in Chinese Han T2DM patients.

Variants in the gene \(ABCC8\) have been reported to be associated with defects in the \(β\)-cell mass and/or \(β\)-cell function, leading to reduced insulin secretion (31). Several pharmacogenomic studies have demonstrated that mutations in \(ABCC8\) genes are the most common cause of neonatal T2DM (32), a topic that has received intense focus in T2DM research, and previous studies have shown that variants in these genes encoding Kir6.2 and SUR1 are associated with susceptibility to T2DM (33).

In contrast to findings in Danish and Canadian populations, we found that the frequency of T allele of \(ABCC8\) rs1801261 in our T2DM patients was significantly higher than that of healthy control group (p<0.01) (Table 2), suggesting that \(ABCC8\) rs1801261 gene polymorphisms might be related to T2DM incidence in the Han population in China and that the risk T-allele is a risk factor for T2DM. The results also showed that the CC genotype of \(ABCC8\)
rs1801261 polymorphism resulted in higher HDL-c levels than the CT genotype in patients with T2DM (p<0.05) (Table 3).

ABCC8 rs1801261 polymorphisms are located in the ABCC8 gene exon region. The SNP changes the C allele to the T allele (ACC→ACT) but does not result in any change in the threonine amino acid at 759 residues (Thr759Thr). Weisnagel et al. found that T allele carriers of the ABCC8 rs1801261 locus had lower insulin levels than noncarriers (12), suggesting a correlation between ABCC8 rs1801261 polymorphisms and insulin secretion. In addition, it has been shown that rs1801261 polymorphisms are associated with the function of β-cells, and the CT genotype in T2DM patients results in a lower level of insulin secretion than the CC genotype (34). Therefore, mutations in the ABCC8 gene may affect the biological function of SUR1 in insulin secretion, thereby influencing the occurrence and development of T2DM.

Polymorphisms of genes involved in drug metabolisms, such as cytochrome P450 (CYP) 2C8 (35) and organic anion-transporting polypeptide 1B1 (OATP1B1), may influence the efficacy of repaglinide and the incidence of adverse effects (36). To exclude the impact of OATP1B and CYP2C8 genetic polymorphisms on the response to

### Table 5. Effects of Different ABCC8 rs1801261 Genotypes on the Clinical Characteristics of Type 2 Diabetes Mellitus Patients before and after Repaglinide Treatment.

| Parameter | CC          | CT          | p value |
|-----------|-------------|-------------|---------|
| N (male/female) | 60 (39/21) | 60 (39/21) | 0.760a |
| FPG (mmol/L) Before | 11.35±1.00 | 9.88±0.30 | 0.085 |
|            After   | 6.58±0.40  | 7.22±0.22  | 0.267 |
|             DV     | -4.77±0.78 | -2.66±0.32 | 0.008*** |
| PPG (mmol/L) Before | 17.89±1.54 | 16.81±0.56 | 0.479 |
|             After   | 10.70±0.35 | 11.03±0.37 | 0.720 |
|             DV     | -7.19±1.57 | -5.78±0.65 | 0.283 |
| FINS (mU/L) Before | 14.78±7.29 | 22.40±3.78 | 0.360 |
|             After   | 9.73±1.04  | 15.94±2.36 | 0.840 |
|             DV     | -5.05±7.32 | -6.46±2.93 | 0.127 |
| HOMA-IR Before | 6.78±3.36  | 9.16±1.50  | 0.568 |
|             After   | 2.78±0.26  | 5.08±0.80  | 0.401 |
|             DV     | -4.00±3.35 | -4.08±1.23 | 0.906 |
| HbA1c (%) Before | 10.52±0.64 | 9.28±0.24  | 0.057 |
|             After   | 7.10±0.31  | 7.04±0.12  | 0.843 |
|             DV     | -3.42±0.41 | -2.24±0.20 | 0.026 |
| TG (mmol/L) Before | 1.46±0.16  | 2.49±0.26  | 0.179 |
|             After   | 1.67±0.40  | 1.97±0.17  | 0.347 |
|             DV     | 0.21±0.36  | -0.52±0.16 | 0.247 |
| TC (mmol/L) Before | 4.98±0.31  | 5.43±0.21  | 0.406 |
|             After   | 4.67±0.39  | 4.89±0.34  | 0.562 |
|             DV     | -0.31±0.38 | -0.54±0.18 | 0.681 |
| HDL-c (mmol/L) Before | 1.39±0.07  | 1.39±0.06  | 0.953 |
|             After   | 1.46±0.18  | 1.33±0.06  | 0.498 |
|             DV     | 0.07±0.21  | -0.06±0.08 | 0.464 |
| LDL-c (mmol/L) Before | 3.26±0.29  | 3.20±0.15  | 0.884 |
|             After   | 3.22±0.39  | 3.05±0.14  | 0.660 |
|             DV     | -0.04±0.40 | -0.15±0.15 | 0.797 |

Data are given as mean±standard error. p values represent statistical difference among the two different genotypes assessed by Student’s t-test. *p values are determined by Mann-Whitney U test. **p values are determined by Pearson chi-square test.

D: DV: differential values (the difference between the pre- and post-administration values).
F: FPG: fasting plasma glucose, PPG: postprandial plasma glucose, FINS: fasting serum insulin, PINS: postprandial serum insulin, HOMA-IR: homeostasis model assessment for insulin resistance, HbA1c: glycated hemoglobin, TG: triglyceride, TC: total cholesterol, HDL-c: high-density lipoprotein-cholesterol, LDL-c: low-density lipoprotein-cholesterol.
repaglinide, participants with the same OATP1B1 521TT and CYP2C8*3 139 Arg genotypes but different ABCC8 rs1801261 genotypes were randomly selected. After eight consecutive weeks of repaglinide treatment, the levels of FPG, 2-HPG, HbA1c, TC, TG and HOMA-IR were significantly lower in these T2DM patients, indicating that repaglinide can improve the blood sugar and lipid metabolism values.

C/C homozygotes of the ABCC8 exon16-3T/C variant reportedly responded better to repaglinide with regard to insulin sensitivity than those with the T/C or T/T genotypes; however, no significant effect of the ABCC8 exon16-3T/C variant on repaglinide treatment was noted (37). The results of another study were not consistent, but C allele carriers were found to be more likely to develop higher TG concentrations after 6 months than noncarriers (38). However, the effect of ABCC8 exon16-3T/C variants on the therapeutic efficacy of repaglinide has not been reported, and this should be explained by future functional research on the polymorphisms of ABCC8 in addition to a population study.

In the present study, the association between ABCC8 rs1801261 and repaglinide efficacy was examined. The results showed that repaglinide treatment had attenuated efficacy on the FPG in patients with the CT genotype of ABCC8 rs1801261 (p<0.01). Patients with the CC genotype of ABCC8 rs1801261 have shown a significant reduction in the levels of FPG than in patients with the CT genotype, suggesting that repaglinide is less effective in reducing postprandial blood glucose in T2DM patients who carry the T-allele.

**Conclusion**

Our findings will aid in the development of better strategies for predicting therapeutic efficacy and controlling blood glucose in T2DM patients carrying different ABCC8 genotypes. However, more detailed genetic and functional investigations will be needed in order to examine the effects of ABCC8 variants on repaglinide therapy and provide more experimental evidence supporting patient-tailored therapy.

The authors state that they have no Conflict of Interest (COI).

**Financial Support**

This work was supported by the Natural Science Foundation of the Jiangsu Higher Education Institutions of China [No. 18 KJA350002]; the Natural Science Foundation of Jiangsu Province [No. BK20181470]; the Science and Technology Foundation of Xuzhou [No. KC18044]; the Natural Science Foundation of China [No. 81403001]; the special financial grant from the China Postdoctoral Science Foundation [No. 2016T90510]; the China Postdoctoral Science Foundation funded project [No. 2015M580474]; the Six talent peaks project in Jiangsu Province [YY-045]; the Qing Lan Project in Jiangsu Province and A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions [PAPD].

**Acknowledgement**

Our thanks to all volunteers in this study for their cooperation and the physicians from the Department of Endocrinology, the Affiliated Hospital of Xuzhou Medical University for their support.

**References**

1. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103: 137-149, 2014.
2. Chan JCN, Malik V, Jia W, et al. Diabetes in Asia epidemiology, risk factors, and pathophysiology. JAMA 301: 2129-2140, 2009.
3. Wane J, Fane H, Done B, et al. Effects of free anthraquinones extract from the rhubarb on cell proliferation and accumulation of extracellular matrix in high glucose cultured-mesangial cells. Korean J Physiol Pharmacol 19: 485-489, 2015.
4. Kwak SH, Park KS. Recent progress in genetic and epigenetic research on type 2 diabetes. Exp Mol Med 48: e220, 2016.
5. Rheinheimer J, de Souza BM, Cardoso NS, Bauer AC, Crispim D.
Current role of the NLRP3 inflammasome on obesity and insulin resistance: a systematic review. Metabolism 74: 1-9, 2017.
6. Prudente S, Sesti G, Pandolfi A, Andreozzi F, Consoli A, Trischitta V. The mammalian tribbles homolog TRIB3, glucose homeostasis, and cardiovascular diseases. Endocr Rev 33: 526-546, 2012.
7. Schwenk RW, Vogel H, Schuermann A. Genetic and epigenetic control of metabolic health. Mol Metab 2: 337-347, 2013.
8. Aguilar-Bryan L, Bryan J. Molecular biology of adenosine triphosphate-sensitive potassium channels. Endocr Rev 20: 101-135, 1999.
9. Ahlgvist E, Ahluwalia TS, Groop L. Genetics of type 2 diabetes. Clin Chem 57: 241-254, 2011.
10. Burke MA, Mutharasan RK, Ardehali H. The sulfonylurea receptor, an atypical ATP-binding cassette protein, and its regulation of the Kir(ATP) channel. Circ Res 102: 164-176, 2008.
11. Hansen T, Echwald SM, Hansen L, et al. Decreased tolbutamide-stimulated insulin secretion in healthy subjects with sequence variants in the high-affinity sulfonylurea receptor gene. Diabetes 47: 598-605, 1998.
12. Weinsagel SJ, Rankinen T, Nadeau A, et al. Decreased fasting and oral glucose stimulated C-peptide in non-diabetic subjects with sequence variants in the sulfonylurea receptor 1 gene. Diabetes 50: 697-702, 2001.
13. Hart LM, de Knijff P, Dekker JM, et al. Variants in the sulfonylurea receptor gene: association of the exon 16-3t variant with Type II diabetes mellitus in Dutch Caucasians. Diabetologia 42: 617-620, 1999.
14. Gloyan AL, Hashim Y, Ashcroft SJH, Ashfield R, Wiltshire S, Turner RC; UK Prospective Diabetes Study. Association studies of variants in promoter and coding regions of beta-cell ATP sensitive K+ channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53). Diabet Med 18: 206-212, 2001. Erratum in: Diabet Med 20: 252,2003.
15. Matharoo K, Arora P, Bharwani AJ. Association of adiponectin (AdipoQ) and sulfonylurea receptor (ABCC8) gene polymorphisms with Type 2 Diabetes in North Indian population of Punjab. Gene 527: 228-234, 2013.
16. Rissanen J, Markkanen A, Kärkkäinen P, et al. Sulfonylurea receptor 1 gene variants are associated with gestational diabetes and type 2 diabetes but not with altered secretion of insulin. Diabetes Care 23: 70-73, 2000.
17. American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment. Sec. 8. In Standards of Medical Care in Diabetes-2017. Diabetes Care 40: 985, 2017. Erratum in: Diabetes Care 40 (Suppl. 1): S64-S74, 2017.
18. Norris JM, Rich SS. Genetics of glucose homeostasis implications for insulin resistance and metabolic syndrome. Arterioscler Thromb Vasc Biol 32: 2091-2096, 2012.
19. Gribble FM, Reimann F. Differential selectivity of insulin secretagogues - mechanisms, clinical implications, and drug interactions. J Diabetes Complications 17 (Suppl): 11-15, 2003.
20. Seino S, Sugawara K, Yokoi N, Takahashi H. β-Cell signalling and insulin secretagogues: a path for improved diabetes therapy. Diabetes, Obes Metab 19 (Suppl): 22-29, 2017.
21. Hemmingsen B, Sonne DP, Metzendorf M-I, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev 10: CD012151, 2016.
22. Scott LJ. Repaglinide a review of its use in type 2 diabetes mellitus. Drugs 72: 249-272, 2012.
23. Yu L, Shi D, Ma L, Zhou Q, Zeng S. Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos 34: 278-287, 2013.
24. Yoshida K, Maeda K, Sugiyama Y. Transporter-mediated drug-drug interactions involving OATP substrates: predictions based on in vitro inhibition studies. Clin Pharmacol Ther 91: 1053-1064, 2012.
25. Qin W, Zhang R, Hu C, et al. A variation in NOS1AP gene is associated with repaglinide efficacy on insulin resistance in type 2 diabetes of Chinese. Acta Pharmacol Sin 31: 450-454, 2010.
26. Yu W, Hu C, Zhang R, et al. Effects of KCNN1 polymorphisms on the therapeutic efficacy of oral antidiabetic drugs in Chinese patients with type 2 diabetes. Clin Pharmacol Ther 89: 437-442, 2011.
27. Yu M, Xu XJ, Yin JY, et al. KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes. Clin Pharmacol Ther 87: 330-335, 2010.
28. Sheng F-F, Dai X-P, Qu J, et al. NAMPT-3186CT polymorphism affects repaglinide response in Chinese patients with type 2 diabetes mellitus. Clin Exp Pharmacol Physiol 38: 550-554, 2011.
29. Gong Z-C, Huang Q, Dai X-P, et al. NeuroD1 A45T and PAX4 R121W polymorphisms are associated with plasma glucose level of repaglinide monotherapy in Chinese patients with type 2 diabetes. Br J Clin Pharmacol 74: 501-509, 2012.
30. Huang Q, Yin JY, Dai XP, et al. Association analysis of SLC30A8 (AdipoQ) and sulphonylurea receptor (ABCC8) gene polymorphisms with Type 2 Diabetes in North Indian population. Diabetol Metab 20: 252,2003.
31. Brunetti A, Chieffi E, Fatti D. Recent advances in the molecular genetics of type 2 diabetes mellitus. World J Diabetes 5: 128-140, 2014.
32. Remedi MS, Friedman JB, Nichols CG. Diabetes induced by gain-of-function mutations in the Kir6.1 subunit of the K-ATP channel. J Gen Physiol 149: 75-84, 2017.
33. Sokolova EA, Bondar IA, Shabelnikova OY, Pyankova OV, Filipenko ML. Replication of KCNJ11 (p.E23K) and ABCC8 (p.S1369A) Association in Russian Diabetes Mellitus 2 Type Cohort and Meta-Analisis. Plos One 10: e0124662, 2015.
34. Reis AF, Hani EH, Beressi N, et al. Allelic variation in exon 18 of the sulfonylurea receptor 1 (SUR1) gene, insulin secretion and insulin sensitivity in non-diabetic relatives of type 2 diabetic subjects. Diabetes Metab 28: 209-215, 2002.
35. Backman JT, Filippula AM, Niemi M, Neuvonen PJ. Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev 68: 168-241, 2016.
36. Gertz M, Tsamandouras N, Sall C, Houston JB, Galetin A. Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and drug interactions involving OATP substrates: predictions based on in vitro inhibition studies. Pharm Res 31: 2367-2382, 2014.
37. He Y-y, Zhang R, Shao X-y, et al. Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese type 2 diabetics on sulfonylurea therapy. Genet Test Mol Biomark 16: 924-930, 2012.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).